Compare · ISRG vs JNJ
ISRG vs JNJ
Side-by-side comparison of Intuitive Surgical Inc. (ISRG) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ISRG focuses on Industrial Specialties, while JNJ focuses on Biotechnology: Pharmaceutical Preparations.
- JNJ is the larger of the two at $675.03B, about 4.3x ISRG ($155.83B).
- Over the past year, ISRG is down 21.5% and JNJ is up 44.2% - JNJ leads by 65.7 points.
- JNJ has been more active in the news (16 items in the past 4 weeks vs 15 for ISRG).
- Both have 25 recent analyst ratings on file.
- Company
- Intuitive Surgical Inc.
- Johnson & Johnson
- Price
- -
- -
- Market cap
- $155.83B
- $675.03B
- 1M return
- +6.52%
- +12.78%
- 1Y return
- -21.51%
- +44.19%
- Industry
- Industrial Specialties
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2000
- News (4w)
- 15
- 16
- Recent ratings
- 25
- 25
Intuitive Surgical Inc.
Intuitive Surgical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets da Vinci surgical systems, and related instruments and accessories in the United States and internationally. The company's da Vinci Surgical System include surgeon's consoles, patient-side carts, 3-D HD vision systems, skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures. It also manufactures EndoWrist instruments, such as forceps, scissors, electrocautery tools, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures; and provides SimNow, a cloud-enabled simulation platform, which allows surgeons to learn and practice their surgical skills; Iris, an augmented reality imaging product for use in kidney procedures; and Intuitive Cloud that enables proactive monitoring and software updates. In addition, the company offers EndoWrist Stapler, a wristed stapling instrument for resection, transection, and creation of anastomoses; EndoWrist One Vessel Sealers that are wristed single-use instruments for bipolar coagulation and mechanical transection of vessels up to 7mm in diameter and tissue bundles that fit in the jaws of the instrument; E-100 generator, an electrosurgical generator; SureForm 45 Curved-Tip stapler; and SynchroSeal for sealing and transection with a single pedal press. Additionally, the company sells various accessories comprising sterile drapes for ensuring sterile field during surgery; and vision products that include replacement 3D stereo endoscopes, camera heads, light guides, and other items that facilitate the use of the da Vinci Surgical System, as well as Ion endoluminal system for biopsies. Intuitive Surgical, Inc. was founded in 1995 and is headquartered in Sunnyvale, California.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest ISRG
- Director Guthart Gary S sold $4,573,370 worth of shares (10,000 units at $457.34) as part of a pre-agreed trading plan (SEC Form 4)
- Director Barratt Craig H exercised 1,150 shares at a strike of $90.49 and sold $529,003 worth of shares (1,150 units at $460.00) as part of a pre-agreed trading plan (SEC Form 4)
- Intuitive Surgical Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Intuitive Appoints Aaron Martin to its Board of Directors
- EVP & Chief Mfg and Supply Cha Brosius Mark sold $55,896 worth of shares (124 units at $450.77) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 457 units (SEC Form 4)
- VP Corporate Controller Widman Fredrik exercised 5,448 shares at a strike of $201.07 and sold $2,375,628 worth of shares (5,448 units at $436.06) as part of a pre-agreed trading plan (SEC Form 4)
- EVP & Chief Mfg and Supply Cha Brosius Mark sold $82,044 worth of shares (183 units at $448.33) as part of a pre-agreed trading plan (SEC Form 4)
- Director Barratt Craig H sold $510,370 worth of shares (1,150 units at $443.80) as part of a pre-agreed trading plan (SEC Form 4)
- VP Corporate Controller Widman Fredrik sold $1,834,124 worth of shares (4,047 units at $453.21) as part of a pre-agreed trading plan (SEC Form 4)
- SVP Chief Human Resources Offi Wadors Patricia L sold $478,416 worth of shares (1,078 units at $443.80) as part of a pre-agreed trading plan (SEC Form 4)
Latest JNJ
- Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study
- Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
- Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
- Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
- FDA Approval for RYBREVANT FASPRO issued to JANSSEN BIOTECH
- Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
- Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
- Johnson & Johnson to Host Enterprise Business Review
- SEC Form 13F-HR filed by Johnson & Johnson
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer